ClinicalTrials.gg
RecruitingNCT07853040Updated Nov 17, 2026

A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment

A Phase 1 interventional study of INCB161734 in Hepatic Insufficiency and Liver Diseases, sponsored by Incyte Corporation. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

Updated Nov 17, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Hepatic Insufficiency with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Hepatic Insufficiency · United States.

Planned enrollment
30th of 49
24 · median 28
Started
2026
with 3 others
Phase 1
43 of 53
4 open now
Registered
53rd of 53
by date
Lead sponsor
2 of 53
Incyte Corporation

Among the 53 studies in Hepatic Insufficiency with a site in United States, this one is the 30th largest by planned enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2026, is one of 43 in phase 1, and was the 53rd registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

4 of the 53 studies in Hepatic Insufficiency with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Hepatic Insufficiency studies recruiting now, 3 (30%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Hepatic Insufficiency with a site in United States, or all of them as a file.
02

Study summary

This study is conducted to evaluate the pharmacokinetics and safety of INCB161734 in participants with hepatic impairment.

03

Conditions studied

  • Hepatic Insufficiency
  • Liver Diseases

Keywords

  • hepatic impairment
  • liver impairment (moderate and severe)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to comprehend and willingness to sign a written ICF for the study.
  • Age 18 to 80 years (inclusive) at the time of signing the ICF.
  • Moderate or severe hepatic impairment based on score.
  • Medical findings consistent with the degree of hepatic dysfunction, determined by medical history, physical examination, vital sign measurements, 12-lead ECGs, and clinical laboratory examinations at screening and check-in.
  • of 18.0 to 44.0 kg/m2 (inclusive) at screening.
  • Ability to swallow and retain oral tablets.
  • Willingness to avoid pregnancy or fathering children.

Exclusion criteria

Exclusion Criteria:

  • In the opinion of the investigator, history of uncontrolled or unstable cardiovascular, respiratory, renal, GI, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months before screening or evidence of rapidly deteriorating hepatic function.
  • History or current diagnosis of uncontrolled or significant cardiac disease indicating significant risk of safety for participation in the study.
  • Current, functioning organ transplant or on the national transplant list and expected to receive a transplant within 3 months.
  • History of an disease diagnosis (eg, myasthenia gravis).
  • History of within 5 years before screening, with the exception of cured basal cell carcinoma, squamous cell carcinoma of the skin, ductal carcinoma in situ, or Gleason 6 prostate cancer.
  • History of GI disease or surgery (cholecystectomy and appendectomy are allowed) that could impact the absorption of study drug.
  • Severe ascites (ascites requiring paracentesis more than twice every 4 weeks) or encephalopathy ≥ Grade 2 (precludes them from understanding and signing an ICF).
  • Any major surgery within 4 weeks before screening.
  • Donation of blood within 4 weeks before screening (within 2 weeks for plasma only).
  • Blood transfusion within 4 weeks before check-in (Day -1).
  • Current or recent history (within 30 days before screening) of a clinically significant bacterial, fungal, parasitic, or mycobacterial infection, or currently receiving systemic antibiotics or current clinically significant viral infection at screening or check-in (Day -1).
  • History of alcoholism within 3 months before screening.
  • Positive breath, urine, or blood test for ethanol or positive serum or urine screen for drugs of abuse that is not otherwise explained by permitted concomitant medications.
  • Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before study drug administration with another medication or current enrollment in another investigational drug study.
  • Current treatment or treatment within 15 days or 5 half-lives (whichever is longer) before study drug administration with an inducer or inhibitor of , P-gp, or BCRP.
  • Use of prescription drugs (including hormonal ) within 14 days before study drug administration or nonprescription medications/products (including megadose vitamins, minerals, and phytotherapeutic, herbal, or plant-derived preparations as well as pre/probiotics) within 7 days before study drug administration.

    • Note 1: Occasional acetaminophen, standard-dose ibuprofen, and standard-dose vitamins are permitted.
    • Note 2: Established therapy for hepatic disease, or the treatment of associated disorders, that has been stable for at least 7 days prior to study drug administration is allowed if approved by the medical monitor and investigator.
  • Consumption of alcohol within 1 month before screening.
  • Consumption of caffeine-containing foods and beverages within 3 days before check-in (Day -1).
  • Consumption of Seville oranges, grapefruits, pomelos, exotic citrus fruits, grapefruit hybrids, or fruit juices within 7 days before the first dose of study drug.
  • Current use of prohibited medication.
  • Receipt of live (including attenuated) vaccines or anticipation of need for such a vaccine during the study. (Note: Non-live or inactivated vaccines allowed up to 2 weeks before study drug administration.).
  • Known or severe reaction to INCB161734 or of INCB161734.
  • History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator.
  • Inability to undergo venipuncture or tolerate venous access.
  • Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of the study data.
  • Currently smoke > 10 cigarettes per day, or equivalent use of other tobacco- or nicotine-containing products, and are unwilling to refrain from tobacco or nicotine use on treatment days and abide by CRU restrictions.
  • Women who are pregnant or breastfeeding.
  • New medication requirement or an increase in dose for hepatic encephalopathy within 3 months prior to check-in.
  • Current portal systemic shunt.
  • Esophageal banding within 3 months prior to check-in or required any other treatment for GI bleeding within 6 months prior to check-in. Hemorrhoidal banding is permitted.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Moderate hepatic impairment

    Participants with moderate hepatic impairment will be enrolled in Cohort 1.

    Drug: INCB161734

  • Experimental
    Cohort 2: Severe hepatic impairment

    Participants with severe hepatic impairment will be enrolled in Cohort 2.

    Drug: INCB161734

Interventions

06

What researchers measure

Primary outcomes

  1. PK for plasma INCB161734: Cmax

    Defined as the maximum plasma concentration.

    Time frame: Up to approximately 1.5 months

  2. PK for plasma INCB161734: AUClast

    Defined as the area under the concentration-time curve from time zero to time of the last quantifiable concentration.

    Time frame: Up to approximately 1.5 months

  3. PK for plasma INCB161734: AUCinf

    Defined as the area under concentration-time curve from time zero extrapolated to infinity.

    Time frame: Up to approximately 1.5 months

Secondary outcomes

  1. Number of Treatment-Emergent Adverse Events (TEAEs)

    Adverse events reported for the first time or worsening of a pre-existing event, occurring after first dose of study drug.

    Time frame: Up to approximately 1.5 months and 15 days

  2. PK for plasma INCB161734: Tmax

    Defined as the time to maximum concentration.

    Time frame: Up to approximately 1.5 months

  3. PK for plasma INCB161734: t½

    Defined as the terminal-phase half-life.

    Time frame: Up to approximately 1.5 months

  4. PK for plasma INCB161734: Tlast

    Defined as the time at which the last quantifiable concentration is observed.

    Time frame: Up to approximately 1.5 months

  5. PK for plasma INCB161734: CL/F

    Defined as the apparent clearance.

    Time frame: Up to approximately 1.5 months

  6. PK for plasma INCB161734: Vz/F

    Defined as the apparent volume of distribution.

    Time frame: Up to approximately 1.5 months

  7. PK for plasma INCB161734: AUCextrap%

    Defined as the percentage of area under the plasma concentration-time curve from time zero extrapolated to infinity obtained by forward extrapolation.

    Time frame: Up to approximately 1.5 months

07

Study locations

3 of 3 sites recruiting
  • Arizona Clinical Trials - the Institute For Liver Health
    Chandler, Arizona 85225, United States
    Recruiting
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
    Recruiting
  • Texas Liver Institute - American Research Corporation
    San Antonio, Texas 78215, United States
    Recruiting
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Mar 2027, 5 months after the start.

Of 39 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's planned 5 months is below that.

Counting every sponsor, half of 42 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 1, 2026
StartActual
Oct 27, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
3 sites added — first site in United States
Show 3 added (3 United States)
  • Arizona Clinical Trials - the Institute For Liver Health · Chandler, United States
  • Orlando Clinical Research Center · Orlando, United States
  • Texas Liver Institute - American Research Corporation · San Antonio, United States
Nov 17, 2026
Start date
Oct 13, 2026→Oct 27, 2026 (actual)
Nov 17, 2026
Registered
First appeared on the registry
Oct 1, 2026
Show all 2 updates
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    3 sites added — first site in United States
    Show 3 added (3 United States)
    • Arizona Clinical Trials - the Institute For Liver Health · Chandler, United States
    • Orlando Clinical Research Center · Orlando, United States
    • Texas Liver Institute - American Research Corporation · San Antonio, United States
    Start date Oct 13, 2026→Oct 27, 2026 (now actual)
    + 2 other changes: verification date and references
  2. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07853040
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Oct 27, 2026
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Incyte Corporation Call Center (US)
Contact
medinfo@incyte.com
1.855.463.3463
Incyte Corporation Call Center (ex-US)
Contact
eumedinfo@incyte.com
+800 00027423
Incyte Medical Monitor
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KRAS G12D Inhibitor INCB161734

Start the discussion